Phase II study Evaluating Tamibarotene

July 16, 2009



Dear Colleagues:

NorthShore University Hospital is participating in a Phase II study for adult patients with relapsed or refractory acute promyelocytic leukemia (APL) who have been previously treated with ATRA & Arsenic Trioxide. The trial is evaluating Tamibarotene, an orally administered synthetic retinoid. In vitro studies show that Tamibarotene does not substantially bind to CRABP, suggesting possible therapeutic efficacy in patients with ATRA-resistant APL.

If you have any patients that might benefit from this study or would like further information, please call my office at 516-734-8959.


Sincerely,

Steven L. Allen
Associate Chief, Division of Hematology
NorthShoreUniversityHospital
MonterCancerCenter